PL1789434T3 - Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek - Google Patents

Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek

Info

Publication number
PL1789434T3
PL1789434T3 PL05775826T PL05775826T PL1789434T3 PL 1789434 T3 PL1789434 T3 PL 1789434T3 PL 05775826 T PL05775826 T PL 05775826T PL 05775826 T PL05775826 T PL 05775826T PL 1789434 T3 PL1789434 T3 PL 1789434T3
Authority
PL
Poland
Prior art keywords
aminomethane
hydroxymethyl
polypeptides
peptides
stabilization
Prior art date
Application number
PL05775826T
Other languages
English (en)
Inventor
Ingun Christiansen
Arne Staby
Original Assignee
Novo Nordisk As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As filed Critical Novo Nordisk As
Publication of PL1789434T3 publication Critical patent/PL1789434T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL05775826T 2004-08-31 2005-08-26 Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek PL1789434T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200401310 2004-08-31
PCT/EP2005/054209 WO2006024631A2 (en) 2004-08-31 2005-08-26 Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins
EP05775826.0A EP1789434B1 (en) 2004-08-31 2005-08-26 Use of tris(hydroxymethyl) aminomethane for the stabilization of peptides, polypeptides and proteins

Publications (1)

Publication Number Publication Date
PL1789434T3 true PL1789434T3 (pl) 2014-07-31

Family

ID=35311457

Family Applications (1)

Application Number Title Priority Date Filing Date
PL05775826T PL1789434T3 (pl) 2004-08-31 2005-08-26 Zastosowanie tris(hydroksymetylo)aminometanu do stabilizacji peptydów, polipeptydów i białek

Country Status (6)

Country Link
US (1) US8710181B2 (pl)
EP (1) EP1789434B1 (pl)
JP (1) JP4965446B2 (pl)
ES (1) ES2442223T3 (pl)
PL (1) PL1789434T3 (pl)
WO (1) WO2006024631A2 (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070148228A1 (en) * 1999-02-22 2007-06-28 Merrion Research I Limited Solid oral dosage form containing an enhancer
US8119159B2 (en) * 1999-02-22 2012-02-21 Merrion Research Iii Limited Solid oral dosage form containing an enhancer
US7658938B2 (en) * 1999-02-22 2010-02-09 Merrion Reasearch III Limited Solid oral dosage form containing an enhancer
BRPI0710503A2 (pt) * 2006-04-07 2011-08-16 Merrion Res Iii Ltd uso de uma composição farmacêutica, composição farmacêutica, e, forma de dosagem oral
US20090280169A1 (en) * 2008-05-07 2009-11-12 Merrion Research Iii Limited Compositions of peptides and processes of preparation thereof
TWI451876B (zh) * 2008-06-13 2014-09-11 Lilly Co Eli 聚乙二醇化之離脯胰島素化合物
US8907059B2 (en) * 2008-11-14 2014-12-09 Bio-Rad Laboratories, Inc. Phosphopeptide enrichment of compositions by fractionation on ceramic hydroxyapatite
TWI480286B (zh) * 2009-02-25 2015-04-11 Merrion Res Iii Ltd 雙膦酸鹽類組合物及藥物遞送
US20110182985A1 (en) * 2010-01-28 2011-07-28 Coughlan David C Solid Pharmaceutical Composition with Enhancers and Methods of Preparing thereof
US9089484B2 (en) * 2010-03-26 2015-07-28 Merrion Research Iii Limited Pharmaceutical compositions of selective factor Xa inhibitors for oral administration
EP2661273A4 (en) 2011-01-07 2014-06-04 Merrion Res Iii Ltd IRON PHARMACEUTICAL COMPOSITIONS FOR ORAL ADMINISTRATION
WO2013158276A1 (en) * 2012-04-20 2013-10-24 Children's Hospital Medical Center Antibody binding microbial heparin binding motif to retard or prevent microbial biofilm formation on implanted medical devices
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
HUE035803T2 (en) 2012-12-21 2018-05-28 Sanofi Sa Dual GLP1 / GIP or trigonal GLP1 / GIP / glucagon agonists
CN103321100B (zh) * 2013-06-26 2015-07-22 广东工业大学 一种纸张脱酸剂及其使用方法
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/升糖素受體促效劑
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
JP7211704B2 (ja) 2015-01-29 2023-01-24 ノヴォ ノルディスク アー/エス Glp-1アゴニスト及び腸溶コーティングを含む錠剤
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重glp-1/升糖素受體促效劑之新毒蜥外泌肽(exendin-4)衍生物
CN110526982B (zh) * 2018-05-23 2023-08-01 信立泰(成都)生物技术有限公司 一种人胰高血糖素样肽-1类似物融合蛋白的纯化方法
CN109851667A (zh) * 2018-12-29 2019-06-07 江苏万邦医药科技有限公司 一种德谷胰岛素前体的纯化方法
JPWO2022173006A1 (pl) * 2021-02-12 2022-08-18
GB202102258D0 (en) * 2021-02-17 2021-03-31 Arecor Ltd Novel composition
WO2023036862A1 (en) * 2021-09-10 2023-03-16 Zealand Pharma A/S Process for formulating compositions comprising glucagon-like-peptide-2 (glp-2) analogues

Family Cites Families (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4468346A (en) * 1983-10-27 1984-08-28 The United States Of America As Represented By The Secretary Of Agriculture Monoclonal antibodies to porcine immunoglobulins
DE3885459T2 (de) 1987-05-14 1994-03-24 Commw Scient Ind Res Org Molkeproteinfraktionen.
JPH03505401A (ja) 1988-06-27 1991-11-28 ジェネックス・コーポレーション 組換えタンパク質の培養培地への熱放出
EP0431679B1 (en) 1989-12-05 1994-10-19 Merck & Co. Inc. Method of stabilizing recombinant hepatitis B virus surface proteins from yeast
DE4002066A1 (de) 1990-01-25 1991-08-01 Basf Ag Verfahren zur abtrennung von riboflavin aus fermentationssuspensionen
US5272135A (en) 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
SE9101381D0 (sv) 1991-05-07 1991-05-07 Tomas Moks Peptide hormone solution
US5206219A (en) 1991-11-25 1993-04-27 Applied Analytical Industries, Inc. Oral compositions of proteinaceous medicaments
SG45449A1 (en) 1992-05-13 1998-01-16 Sandoz Ltd Ophthalmic compositions
US6284727B1 (en) * 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
GB9320782D0 (en) * 1993-10-08 1993-12-01 Univ Leeds Innovations Ltd Stabilising of proteins on solution
WO1995013825A1 (en) 1993-11-19 1995-05-26 G.D. Searle & Co. TRANSDERMAL COMPOSITION OF N-[N-[5-[4-(AMINOIMINOMETHYL)PHENYL]-1-OXOPENTYL]-L-α-ASPARTYL]-L-PHENYLALANINE OR ITS ESTERS AND THEIR PHARMACEUTICALLY ACCEPTABLE SALTS
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
AU1847695A (en) 1994-02-22 1995-09-04 Syntex-Synergen Neuroscience Joint Venture, The Pharmaceutical formulations of cntf
US5652216A (en) 1994-05-26 1997-07-29 Novo Nordisk A/S Pharmaceutical preparation
ES2316664T3 (es) 1994-08-05 2009-04-16 BAUSCH & LOMB INCORPORATED Un metodo para envasas una lente intraocular.
DK0699687T3 (da) 1994-08-31 2004-04-26 Mitsubishi Pharma Corp Fremgangsmåde til oprensning af rekombinant humant serumalbumin
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69529998D1 (de) 1994-12-23 2003-04-24 Novo Nordisk As Glp-1 zusammensetzungen mit verlängerter wirkdauer
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
US5834428A (en) 1995-04-14 1998-11-10 1149336 Ontario Inc. Glucagon-like peptide-2 and its therapeutic use
EP0828753B1 (en) 1995-06-02 2003-03-26 Novozymes A/S Al/Fe-TREATMENT OF A PROTEIN SOLUTION, FOLLOWED BY MEMBRANE CONCENTRATION
US5631347A (en) 1995-06-07 1997-05-20 Eli Lilly And Company Reducing gelation of a fatty acid-acylated protein
JPH10101696A (ja) 1996-08-08 1998-04-21 Shinotesuto:Kk 形質転換体にて発現される蛋白質に含まれる夾雑物質の除去方法及び精製蛋白質
DE122009000079I2 (de) 1996-08-30 2011-06-16 Novo Nordisk As Novo Alle Glp-1 derivate
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
EP0998942A4 (en) 1997-01-20 2006-08-16 Japan Energy Corp METHOD FOR STABILIZING PEPTIDES AND FREEZERED MEDICINAL COMPOSITIONS THEREOF
CA2236519C (en) 1997-05-02 2011-09-13 1149336 Ontario Inc. Methods of enhancing functioning of the large intestine
WO1999016417A1 (en) 1997-10-01 1999-04-08 Flemington Pharmaceutical Corporation Buccal, polar and non-polar spray or capsule
ES2195409T3 (es) * 1997-10-24 2003-12-01 Genentech Inc Purificacion de moleculas.
AU1617399A (en) 1997-12-05 1999-06-28 Eli Lilly And Company Glp-1 formulations
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
EP1060191B1 (en) 1998-02-27 2010-04-28 Novo Nordisk A/S Derivatives of glp-1 analogs
AU2610899A (en) 1998-02-27 1999-09-15 Novo Nordisk A/S N-terminally modified glp-1 derivatives
DE69916811T2 (de) 1998-02-27 2005-04-14 Novo Nordisk A/S Glp-1 derivate mit einem helix-gehalt über 25 %, die partiell strukturierte mizellenartige aggregate bilden
DE69918070T2 (de) 1998-03-13 2005-08-25 Novo Nordisk A/S Stabilisierte, wässrige Glukagonlösungen, enthaltend Detergenzien
WO2000015224A1 (en) 1998-09-17 2000-03-23 Eli Lilly And Company Protein formulations
CA2358107C (en) 1998-12-22 2011-08-23 Eli Lilly And Company Shelf-stable formulation of glucagon-like peptide-1
RU2242244C2 (ru) 1999-01-14 2004-12-20 Амилин Фармасьютикалз, Инк. Новые композиции агонистов эксендина и способы их введения
US6444788B1 (en) * 1999-03-15 2002-09-03 Novo Nordisk A/S Ion exchange chromatography of GLP-1, analogs and derivatives thereof
CA2361830A1 (en) 1999-03-17 2000-09-21 Novo Nordisk A/S Method for acylating peptides and novel acylating agents
EP1196189A2 (en) 1999-06-25 2002-04-17 Medtronic MiniMed, Inc. Multiple agent diabetes therapy
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
WO2001043762A2 (en) 1999-12-16 2001-06-21 Eli Lilly And Company Polypeptide compositions with improved stability
GB9930882D0 (en) 1999-12-30 2000-02-23 Nps Allelix Corp GLP-2 formulations
US6734162B2 (en) * 2000-01-24 2004-05-11 Minimed Inc. Mixed buffer system for stabilizing polypeptide formulations
EP1396499A3 (en) 2000-01-27 2004-12-29 Eli Lilly And Company Process for solubilizing glucagon-like peptide 1 (GLP-1) compounds
ATE264870T1 (de) 2000-01-27 2004-05-15 Lilly Co Eli Verfahren zur lösung von glucagon-ähnlichen peptid-1 (glp-1) verbindungen
US6844321B2 (en) 2000-01-31 2005-01-18 Novo Nordisk A/S Crystallization of a GLP-1 analogue
AU2001248277A1 (en) 2000-04-06 2001-10-23 Novo-Nordisk A/S Shock heat treatment of polypeptides
DE60137876D1 (de) 2000-06-16 2009-04-16 Lilly Co Eli Analoge des Glucagon-ähnlichen Peptids-1
JP4798833B2 (ja) 2000-10-24 2011-10-19 一般財団法人化学及血清療法研究所 加熱処理工程を含むヒト血清アルブミンの製造方法
AU2002228608A1 (en) 2000-12-13 2002-06-24 Eli Lilly And Company Amidated glucagon-like peptide-1
US20020151467A1 (en) 2000-12-21 2002-10-17 Leung Frank K. Methods and compositions for oral insulin delivery
GB2371227A (en) 2001-01-10 2002-07-24 Grandis Biotech Gmbh Crystallisation - resistant aqueous growth hormone formulations
DK1360202T3 (da) 2001-02-16 2008-09-22 Conjuchem Biotechnologies Inc Langvarigt glucagon-lignende peptid 2 (GLP-2) til behandling af gastrointestinale sygdomme og lidelser
US6573237B2 (en) 2001-03-16 2003-06-03 Eli Lilly And Company Protein formulations
ES2298378T3 (es) 2001-06-28 2008-05-16 Novo Nordisk A/S Formulacion estable de glp-1 modificado.
CN1335182A (zh) 2001-08-08 2002-02-13 华中科技大学 胰岛素口腔喷剂及其制备工艺
WO2003020201A2 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
EP1448222A4 (en) 2001-10-19 2006-05-17 Lilly Co Eli BIPHASIC MIXTURES OF GLP-1 AND INSULIN
DE60307701T2 (de) * 2002-03-15 2007-10-11 Natimmune A/S Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
EP1494704A1 (en) 2002-04-04 2005-01-12 Novo Nordisk A/S Glp-1 agonist and cardiovascular complications
WO2004029076A2 (en) 2002-09-25 2004-04-08 Novo Nordisk A/S Purification process comprising microfiltration at elevated temperatures
WO2004089985A1 (en) 2003-04-11 2004-10-21 Novo Nordisk A/S Stable pharmaceutical compositions
US8008255B2 (en) 2003-05-30 2011-08-30 Amylin Pharmaceuticals, Inc. Methods and compositions for enhanced transmucosal delivery of peptides and proteins
ES2375056T3 (es) * 2003-06-03 2012-02-24 Novo Nordisk A/S Composiciones pept�?dicas farmacéuticas estabilizadas.
EP1633391B1 (en) * 2003-06-03 2011-10-19 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
AU2004243531B2 (en) 2003-06-03 2009-11-05 Novo Nordisk A/S Stabilized pharmaceutical peptide compositions
JP4800959B2 (ja) 2003-11-13 2011-10-26 ノヴォ ノルディスク アー/エス 糖尿病及び過食症を治療するためのglp−1ペプチド及び短時間作用型インスリンペプチドを含む、非経口投与用の可溶性医薬組成物
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
EP1789075A4 (en) 2004-08-25 2009-07-01 Uab Research Foundation ABSORPTION ENHANCER FOR DRUG ADMINISTRATION

Also Published As

Publication number Publication date
WO2006024631A2 (en) 2006-03-09
ES2442223T3 (es) 2014-02-10
US20080171848A1 (en) 2008-07-17
EP1789434B1 (en) 2013-11-20
WO2006024631A3 (en) 2006-06-15
EP1789434A2 (en) 2007-05-30
JP4965446B2 (ja) 2012-07-04
JP2008511583A (ja) 2008-04-17
US8710181B2 (en) 2014-04-29

Similar Documents

Publication Publication Date Title
IL183405A0 (en) Pancreatic polypeptide family motifs, polypeptides and methods comprising the same
DK1680443T3 (da) Stabiliserede alfa-helix-peptider og anvendelser heraf
WO2006017538A3 (en) Hk1-binding proteins
EP1732581A4 (en) POLYPEPTIDE TRANSDUCTION AND FUSOGENIC PEPTIDES
IL177403A0 (en) Pancreatic polypeptide family polypeptides and pharmaceutical compositions containing the same
EP1699920A4 (en) NEW RECOMBINANT PROTEINS WITH FREE N-TERMINAL THIOL
GB0324368D0 (en) Polypeptides including modified constant regions
IL171109A (en) Glycopegylation methods and proteins/peptides produced by the methods
WO2007007192A8 (en) Use of ionic matrices for maldi mass spectrometry analysis of tissue sections
WO2004087874A3 (en) Novel nucleic acids and polypeptides
WO2005037236A3 (en) Novel heat shock protein 20-related polypeptides and uses therefor
EP1614695A4 (en) POLYPEPTIDE
ZA200508028B (en) Glycopegylation methods and proteins/peptides produced by the methods
FI20040655L (fi) Proteiini- ja peptidistabilointi
SG10201505948VA (en) Pancreatic Polypeptide Family Motifs, Polypeptides And Methods Comprising The Same
GB0322317D0 (en) Expansin polypeptide
MY142798A (en) Methods for preventing glyconoylation of proteins
GB0521490D0 (en) RFamide-related peptide precursor proteins and RFamide peptides
GB0422110D0 (en) Recombinant proteins
ATE432473T1 (de) Peptide zur unterscheidung von prionen
AU2003280316A8 (en) Zymogen-like protein c polypeptides
GB2441941B (en) An isolated recombinant vaccinia virus complement control protein (HRVCP) polypeptide
WO2006020541A3 (en) Methods for synthesizing polypeptides
DK1615945T3 (da) Glycopegyleringsfremgangsmåder og proteiner/peptider fremstillet ved fremgangsmåderne
GB2415195B (en) Peptides of IRF-1